Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL Inc. are pooling resources to bring GRAIL’s Galleri multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also agreed to invest $110 million in GRAIL at $70.05 per common stock share.¹

“Guided by its commitment to advancing next-generation bio-technologies and improving quality of life, Samsung C&T has continuously invested in innovative companies. The collaboration with GRAIL represents a significant new step—moving beyond investment to a strategic business partnership that provides Samsung with a strong foothold for expanding into the cancer screening field and delivering one of these promising technologies to customers in South Korea and across Asia,” said Jaywoo Kim, executive vice president of Life Science Business at Samsung C&T.

Subject to final execution of definitive agreements, GRAIL and SCT will commercialize the Galleri test in South Korea, with a possible extension into other Asian geographies, including Japan and Singapore. SCT will undertake key activities to drive Galleri’s adoption. Initially, tests will be performed in GRAIL’s clinical laboratory in Research Triangle Park, N.C. 

“We look forward to partnering with Samsung to bring multi-cancer early detection to Asia, beginning in South Korea,” said Sir Harpal Kumar, president, International Business and Biopharma, at GRAIL. “Samsung’s equity investment strengthens our balance sheet and provides further cash runway as we advance through key milestones to secure reimbursement for Galleri in the U.S. and key international markets.”

In addition, SEC and GRAIL plan to explore potential strategic and operational collaborations such as supporting longitudinal genomic-lifestyle clinical research, and the integration of SEC’s health data platform with GRAIL’s technologies and data.

“Our investment in and strategic cooperation with GRAIL is part of our vision to improve the health of billions of people. A potential collaboration with GRAIL could allow for the integration of our AI, our digital care platform, and device ecosystem with GRAIL’s clinical genetic data and technology, which could allow us to provide a level of personalization for our users to help them better understand their health,” said Hon Pak, senior vice president and head of Digital Health Team, Mobile eXperience Business, at Samsung Electronics.

Within South Korea, and potentially Japan and Singapore, GRAIL will partner with SCT as its sole distributor, subject to certain requirements, and GRAIL’s Galleri test will be the exclusive MCED test distributed by SCT. The investment is subject to execution of the definitive collaboration agreements between the parties, as well as customary closing conditions and regulatory approvals. The investment is expected to close in early 2026.

Latham & Watkins served as legal advisor and Morgan Stanley & Co. LLC served as financial advisor to GRAIL. Samsung was advised by Covington & Burling, BKL, and E&Y Han Young (Korea).

The Galleri multi-cancer early detection test is a proactive cancer screening tool. With a simple blood draw, Galleri can detect more than 50 types of cancer before symptoms appear—when they can be easier to treat and are potentially curable.² Galleri is the only available MCED test with demonstrated performance in patients screened for cancer.^2,* The Galleri test doubles the number of cancers detected when added to standard of care cancer screening, and has the lowest false positive rate of any MCED test.^1,2,3,4,** When a cancer signal is found, Galleri provides a cancer signal of origin with high accuracy to help guide an efficient diagnostic work-up.^4,5,6 The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.

Samsung C&T Corporation, a player in industries ranging from construction, trading, fashion and resorts, is actively expanding its portfolio with strategic investments in biopharmaceutical and life sciences. Since its investment in Samsung Biologics and Samsung Bioepis, Samsung C&T continues to invest in innovative technologies and businesses within the biopharma and healthcare sectors. 

Samsung is redefining the worlds of televisions, digital signage, smartphones, wearables, tablets, home appliances and network systems, as well as memory, system LSI and foundry. Samsung is also advancing medical imaging technologies, HVAC solutions and robotics, while creating automotive and audio products through Harman.

GRAIL is a healthcare company on a mission to detect cancer early. GRAIL is focused on alleviating cancer’s global burden by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, Calif., with locations in Washington, D.C.; North Carolina; and the United Kingdom. 

* The Galleri test performance metrics were derived from the outcomes of an interventional clinical study of patients presenting for screening without clinical suspicion of cancer, a study population that reflects the intended use population.
** Test performance metrics do not represent results of a head-to-head comparative study. Separate studies have different designs, objectives, and participant populations, which limits the ability to draw conclusions about comparative performance.

References
¹ Representing a 10% premium to the 15 day VWAP.
² Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
³ GRAIL, Inc. False positive rate. [Data on file: GR-2025-0256]
⁴ Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi: 10.1016/S0140-6736(23)01700-2 
⁵ GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592]
⁶ Hackshaw A, et al. Cancer Cell. 2022;40(2):109-13.